Multi-Platform Milk Metabolomics Identifies Distinctive Biomarker Signatures of Subclinical Ketosis in Dairy Cows
Dairy · 28.05.2026 · 7 (3) · 39
DOI: 10.3390/dairy7030039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dairy, online erschienen am 28.05.2026. Verfasst von Guanshi Zhang und 2 weiteren Autor:innen. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Genome Alberta.
Abstract (Originalsprache)
Ketosis is one of the most economically significant metabolic disorders affecting periparturient dairy cows, causing production losses and predisposing animals to secondary complications. Current blood-based diagnostics are invasive and provide limited insight into the underlying metabolic perturbations. This study employed an integrated three-platform metabolomics approach to characterize milk metabolite alterations in ketotic Holstein dairy cows and to evaluate milk-based biomarker panels for early ketosis detection. Milk samples from 20 healthy control (CON) cows and 6 ketotic cows were collected at 2 weeks postpartum and analyzed by direct injection/liquid chromatography–tandem mass spectrometry (DI/LC-MS/MS), proton nuclear magnetic resonance (1H-NMR) spectroscopy, and inductively coupled plasma mass spectrometry (ICP-MS). Ketosis was confirmed by serum β-hydroxybutyrate concentrations ≥ 1400 μmol/L. Principal component analysis, partial least squares-discriminant analysis, and receiver operating characteristic (ROC) curve analyses were applied. All three platforms discriminated ketotic cows from healthy cows, with clear cluster separation validated by 2000 permutation tests (p < 0.05). DI/LC-MS/MS identified 16 significantly altered metabolites (p < 0.05), with butyrylcarnitine (C4), phosphatidylcholine 30:0 (PC 30:0), ether-linked phosphatidylcholine O-38:3 (PC O-38:3), and citrulline identified as the top discriminatory biomarkers (AUC = 0.920; 95% CI: 0.85–0.98; sensitivity = 91.7%; specificity = 93.3%). ICP-MS revealed significantly reduced selenium (Se, p = 0.017), manganese (Mn, p = 0.045), and chromium (Cr, p = 0.037), as well as elevated cobalt (Co, p = 0.014) in ketotic milk (AUC = 0.870). 1H-NMR detected no individually significant metabolites; however, multivariate analysis distinguished groups (AUC = 0.890), with succinate (numerical fold change: +5.77×; p = 0.059), methanol (−1.94×; not significant), and acetate (+2.88×; not significant) as top VIP contributors. The combined multi-platform biomarker panel (joint classification using top VIP features from all three platforms, without formal data fusion) achieved superior diagnostic performance (AUC = 0.970; 95% CI: 0.93–1.00; sensitivity = 95.0%; specificity = 96.7%). These findings identify coordinated perturbations in glycerophospholipid metabolism, acylcarnitine profiles, amino acid homeostasis, antioxidant mineral status, and energy metabolism during early ketosis, and suggest that milk metabolomics is a promising non-invasive approach for precision dairy health monitoring, pending validation in independent cohorts. We acknowledge the small ketotic group size (n = 6) as a limitation; therefore, these findings should be considered discovery cohort observations requiring prospective validation before clinical translation.
Förderung
- Genome Alberta
Zitieren
APA
Zhang, G., Wishart, D. S., & Ametaj, B. N. (2026). Multi-Platform Milk Metabolomics Identifies Distinctive Biomarker Signatures of Subclinical Ketosis in Dairy Cows. Dairy, 7(3), 39. https://doi.org/10.3390/dairy7030039
Vancouver
Zhang G, Wishart DS, Ametaj BN. Multi-Platform Milk Metabolomics Identifies Distinctive Biomarker Signatures of Subclinical Ketosis in Dairy Cows. Dairy. 2026;7(3):39. doi:10.3390/dairy7030039
BibTeX
@article{Zhang2026,
author = {Zhang, Guanshi and Wishart, David S. and Ametaj, Burim N.},
title = {Multi-Platform Milk Metabolomics Identifies Distinctive Biomarker Signatures of Subclinical Ketosis in Dairy Cows},
journal = {Dairy},
year = {2026},
volume = {7},
number = {3},
pages = {39},
doi = {10.3390/dairy7030039}
}
EUVIMED